Considering their unique physiological and pathophysiological functions, EHMT1/2 have emerged as cancer therapeutic targets and, as such, inhibitors targeting G9a and GLP evolved as a novel approach to cancer treatment [97,98,99]. Here, EHMT2 is linked to cancer.